A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)

Mark D. Wheeler 1 · Margarita Barrientos-Perez 2 · Fu-Sung Lo 3 · Bo Liang 4 · Alison Lunsford 5 · Ólöf Thórisdóttir 4 · Nehama Zuckerman-Levin 6

Received: 22 March 2018 / Revised: 3 July 2018 / Accepted: 4 July 2018 / Published online: 16 July 2018 © The Author(s) 2018

Abstract

There are limited studies evaluating the safety and efficacy of treatments in young people with type 2 diabetes (T2D). This study compared the efficacy and safety of insulin detemir versus neutral protamine Hagedorn (NPH) insulin, both in combination with metformin and lifestyle intervention, in children and adolescents with T2D. This randomized, open-label, phase 3 trial recruited patients (n = 42) aged 10–17 years diagnosed with T2D already receiving metformin ± other oral antidiabetic drugs ± basal insulin. Patients were randomized (1:1) to receive either insulin detemir or NPH insulin, both with the maximum tolerated dose of metformin, and lifestyle intervention, over 26 weeks. Enrollment terminated prematurely after 17 months due to a very slow recruitment rate (12% of the target met). After 26 weeks, the observed mean HbA1c value had decreased by 0.61% points in the insulin detemir group vs. 0.84% points in the NPH insulin group. The rate of symptomatic blood glucose-confirmed hypoglycemic episodes was 0.4 episodes/patient-year of exposure (PYE) for insulin detemir vs. 1.1 episodes/PYE for NPH insulin.

Communicated by Peter de Winter

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00431-018-3205-z) contains supplementary material, which is available to authorized users.

Mark D. Wheeler
mwheeler@peds.arizona.edu

Margarita Barrientos-Perez
marga_barrientos@yahoo.com

Fu-Sung Lo
lofisu@cgmh.org.tw

Bo Liang
bolq@novonordisk.com

Alison Lunsford
alison.lunsford@ttuhsc.edu

Ólöf Thórisdóttir
oto@novonordisk.com

Nehama Zuckerman-Levin
zuckerln@netvision.net.il

1 The University of Arizona Department of Pediatrics, 1501 N. Campbell Avenue, Room 3301, PO Box 245073, Tucson, AZ 85724, USA
2 Servicio de Endocrinología Pediátrica, Hospital Angeles de Puebla, Av. Kepler 2143, Cons. 715 B, Col. Reserva Territorial Atlixcayotl, Puebla, CP 72190 Puebla, Mexico
3 Division of Pediatric Endocrinology & Genetics, Department of Pediatrics, Chung Gung Memorial Hospital, Chung Gung University College of Medicine, No. 5 Fusing Street, Gueishan, Taoyuan County 333, Taiwan
4 Novo Nordisk A/S, Vandtårnsvej 114, 2860 Søborg, Denmark
5 Department of Pediatrics, Texas Tech University Health Sciences Center, 1400 S Coulter Street, Amarillo, TX 79106, USA
6 Pediatric Diabetes Clinic, Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, 31096 Haifa, Israel
Conclusion: No safety issues were revealed with either basal insulin. Due to the low number of patients recruited, no efficacy conclusions could be drawn.

ClinicalTrials.gov identifier: NCT02131272.

What is known:
- There is a growing worldwide epidemic of type 2 diabetes in children and adolescents.
- There is a lack of research and limited treatment options currently available in this population.

What is new:
- No safety issues with insulin detemir or neutral protamine Hagedorn insulin in children and adolescents with type 2 diabetes were observed.
- Improving clinical trial recruitment, along with providing early, efficacious, and safe treatment options, in this population is critical.

Keywords Type 2 diabetes · Insulin detemir · Adolescents · NPH insulin · Children

Abbreviations
ADA American Diabetes Association
AE adverse event
BG blood glucose
BMI body mass index
E number of episodes
FAS full analysis set
FPG fasting plasma glucose
IDet insulin detemir
IU international unit
LOCF last observation carried forward
MTD maximum tolerated dose
NPH neutral protamine Hagedorn
OAD oral antidiabetic drug
PP per protocol
PYE patient-year of exposure
R event rate per patient-year of exposure
SD standard deviation
SDS standard deviation score
SMBG self-measured blood glucose
T2D type 2 diabetes
U unit of insulin

Introduction

Type 2 diabetes (T2D) is considered a growing epidemic in children and adolescents [2], due to factors such as the high prevalence of obesity in young people [26]. According to worldwide data, the estimated incidence of T2D is currently 330 per 100,000 person-years, and the estimated prevalence is 5300 per 100,000 population [4]. In recent years, the USA has witnessed a rapid increase in T2D in youth [15], with approximately 5000 new cases every year [13], and a projected fourfold rise in the number by 2050 [9].

T2D is a progressive disease characterized by hyperglycemia, insulin resistance, and reduced insulin secretion by beta-cells in the pancreas [10]. The rate at which insulin secretion by beta-cells diminishes in T2D is greater in youth (age 10–17 years) than in adults [7], which results in earlier and more aggressive development of diabetes-related complications [3, 18].

First-line management of T2D in children and adolescents includes dietary and exercise lifestyle modifications. Metformin and/or basal insulin are recommended by the American Diabetes Association (ADA) 2018 guidelines and the International Society for Pediatric and Adolescent Diabetes when lifestyle modification alone is insufficient to improve glycemic control [1, 27]. The failure of metformin treatment to maintain glycemic control, and thus, the need to consider starting insulin treatment, occurs sooner in youth than adults due to the rapid progression of T2D in youth [24, 25]. Despite a variety of insulins being used to treat youth-onset T2D, there have been no studies to evaluate insulin for treating the distinct indication of pediatric T2D [16].

Insulin detemir has been shown to offer a weight-sparing effect, improve glycemic control, and reduce the number of hypoglycemic episodes compared with neutral protamine Hagedorn (NPH) insulin [8, 20] in adults with T2D. Furthermore, insulin detemir has previously been shown to be effective and safe in type 1 diabetes in youth as part of a basal–bolus regimen [22], and as such, it may prove beneficial in children and adolescents with T2D. The current trial was conducted to compare the benefits and risks of insulin detemir versus NPH insulin, in combination with metformin, in children and adolescents with T2D with inadequate glycemic control.

Methods

Design

This 26-week, open-label, randomized, two-armed, parallel-group, multicenter, phase 3 trial recruited patients aged 10–17 years with T2D who had insufficient glycemic control with the maximum tolerated dose (MTD) of metformin ± other oral antidiabetic drugs (OADs) ± basal insulin. The study ran between June 2014 and June 2016, screening individuals from Brazil, Hungary, Germany, India, Israel, South Korea, Malaysia, Mexico, Russia, Taiwan, Turkey, and the USA.
(ClinicalTrials.gov identifier: NCT02131272). Written consent was collected from all patients or legally acceptable representatives. An independent data-monitoring committee reviewed and evaluated accumulating safety data from the trial to protect the safety of the patients and evaluate the benefit-versus-risk assessment. The trial was conducted according to the Declaration of Helsinki, Good Clinical Practice (International Conference on Harmonisation), and US Food and Drug Administration Code of Federal Regulations Title 21 312.120.

The study included male and female patients with a diagnosis of T2D at least 3 months prior to screening, and HbA1c ≥ 7.0% and ≤ 10.5% (≥ 53 and ≤ 91 mmol/mol) at the time of screening. Patients were treated with the MTD of metformin for at least 3 months prior to screening or had documented complete metformin intolerance. Other OADs and basal insulin were allowed, and bolus insulin was only allowed as rescue treatment for a maximum of 7 days for the last 3 months prior to screening.

Key exclusion criteria were the presence of known or suspected hypersensitivity to trial products, maturity-onset diabetes of the young, impaired liver function (alanine aminotransferase ≥ 2.5 times the upper limit), known proliferative retinopathy or maculopathy requiring acute treatment, and pregnancy, breastfeeding, or willingness to become pregnant. Furthermore, the trial excluded patients who had been treated with any medication other than metformin ± other OADs ± basal insulin for the indication of diabetes or obesity within 3 months prior to screening.

After an initial 2-week screening period, eligible patients were randomly assigned to either insulin detemir or NPH insulin (1:1 ratio), both in combination with metformin and recommended lifestyle interventions (i.e., diet and exercise) for 26 weeks. A diet and exercise intervention, which followed a family-based behavioral weight-loss approach, was introduced not only to improve glycemic control, but also to motivate patients throughout the study, and was inspired by the educational material used in the TODAY study [23, 25]. The total daily dose of metformin was not changed, unless for safety reasons. Treatment with other OADs was discontinued at randomization.

Insulin detemir 100 U/mL and NPH insulin 100 IU/mL were supplied in a 3 mL pre-filled FlexPen (Novo Nordisk, Bagsvaerd, Denmark) and administered subcutaneously once or twice daily. For insulin-naive patients, insulin detemir and NPH insulin were initiated at a dose of 0.1–0.2 U/kg, with a maximum dose of 10 U, at the investigators’ discretion. Patients who were already receiving basal insulin before the trial were switched to equivalent units of insulin detemir or NPH insulin and maintained their pre-trial daily injection frequency. Insulin detemir and NPH insulin doses were titrated to a target self-measured blood glucose (SMBG) of 4.0–6.0 mmol/L (71–108 mg/dL), based on average pre-breakfast or pre-dinner SMBG measurements taken on any 3 days in the week prior to a site visit/phone contact (Supplementary Table 1).

Endpoints

The primary efficacy endpoint was change in HbA1c from baseline after 26 weeks of treatment. The secondary efficacy endpoints, measured at week 26, were the number of patients achieving HbA1c < 7.0% (53 mmol/mol) (total and without treatment-emergent severe hypoglycemic episodes within the last 14 weeks of treatment) and < 7.5% (58 mmol/mol), and the mean of the 7-point SMBG profile. Additional secondary efficacy endpoints included change from baseline to week 26 in fasting plasma glucose (FPG), body weight standard deviation score (SDS), height SDS, body mass index (BMI), and BMI SDS.

Safety endpoints included incidence of adverse events (AEs) and hypoglycemic events during 26 weeks of treatment. Both total and nocturnal (occurring between 2300 and 0659 hours) treatment-emergent severe (requiring assistance) or blood glucose (BG)-confirmed (BG < 3.1 mmol/L [< 56 mg/dL]) symptomatic episodes were reported.

Statistics

The sample size was determined to show non-inferiority of insulin detemir to NPH insulin, in combination with the MTD of metformin and diet/exercise intervention, in change in HbA1c from baseline after 26 weeks of treatment, using a non-inferiority limit of 0.4%. A total of 358 patients were initially planned to be randomized in this trial to have 80% power and show non-inferiority for both the full analysis set (FAS; i.e., all randomized patients) and the per-protocol (PP) analysis set (i.e., all randomized patients treated for at least 12 weeks and not violating any of the inclusion/exclusion criteria). However, due solely to a very slow recruitment rate, the sponsor decided to stop enrollment at 17 months and offered the 42 recruited patients the opportunity to complete the trial.

Formal statistical analysis was conducted on change in HbA1c from baseline to 8, 16, and 26 weeks using a mixed model for repeated measurements with treatment, age group (two levels: 10–14 years and 15–17 years), prior antidiabetic therapy (two levels: metformin only or metformin in combination with other OAD(s) and/or basal insulin), and the interaction between age group and prior antidiabetic therapy as factors, and baseline HbA1c as a covariate, with all variables nested within week as a factor. The SDS were derived by comparing the measurements taken in the trial with standard growth charts for the USA [12].

As a result of the limited number of patients included in the trial, the planned statistical analysis on the secondary efficacy and safety endpoints was not conducted and therefore only descriptive statistics are used to report these results. The
Results

A total of 71 patients were screened, of whom 29 were screening failures mostly due to not meeting the inclusion criterion of HbA1c 7.0–10.5% (53–91 mmol/mol). Of the 42 patients who were randomized, 39 completed the trial (Supplementary Fig. 1). Baseline characteristics are reported in Table 1; differences noted between the two groups were not unexpected due to the small number of patients recruited.

Efficacy

Observed mean HbA1c decreased largely in the first 16 weeks in both treatment groups (Fig. 1). Median values and range (min; max) for HbA1c with insulin detemir and NPH insulin by week of treatment are shown in Table 2. After 26 weeks of treatment, mean HbA1c had decreased by 0.61% points (6.7 mmol/mol) to 8.11% (65 mmol/mol) in the insulin detemir group and by 0.84% points (9.2 mmol/mol) to 8.11% (65 mmol/mol) in the NPH insulin group. The estimated mean treatment difference at week 26 was 0.17% (95% confidence interval −0.74; 1.09; \( p = 0.3075 \)); however, no efficacy conclusions could be drawn from the primary analysis due to the low number of patients included in the trial.

Secondary efficacy endpoints after 26 weeks of treatment are reported in Table 3. Observed mean FPG values decreased during the 26-week treatment period in both groups, with a numerically smaller change from baseline in the insulin detemir group compared with NPH insulin (−0.335 vs. −2.332 mmol/L, respectively), largely accounted for by the higher baseline FPG value in the NPH insulin group compared with the insulin detemir group. As expected in this trial population [14], observed mean body weight increased in both treatment groups; however, weight gain was numerically lower in the insulin detemir group (1.89 kg) compared with the NPH insulin group (4.00 kg).

The mean insulin dose at baseline was 25.2 U (0.342 U/kg) and 16.2 IU (0.226 IU/kg) in the insulin detemir and NPH insulin groups, respectively. After 26 weeks of treatment, the...
mean basal insulin dose had increased to 69.6 U (0.884 U/kg) in the insulin detemir group and 65.4 IU (0.818 IU/kg) in the NPH insulin group.

Safety

No severe hypoglycemic episodes were reported and the rate of symptomatic BG-confirmed hypoglycemia was low in both treatment groups (Table 4). During 26 weeks of treatment, a total of 30 AEs were reported in eight patients in the insulin detemir group (rate of 3.1 events/PYE) and 41 AEs were reported in 13 patients in the NPH insulin group (rate of 3.9 events/PYE). The most frequently reported AEs (in 10–15% of participants in either of the two treatment groups) were gastroenteritis, headache, oropharyngeal pain, pyrexia, and vomiting. No AEs led to withdrawal from the trial. One serious AE (i.e., migraine) was reported in the NPH insulin group that was moderate in severity and was considered unlikely to be related to the trial product. No deaths were reported.

There were no clinically relevant changes in the development of anti-insulin antibodies in either of the treatment groups from baseline to week 26.

Discussion

This trial was conducted to evaluate the efficacy and safety of insulin detemir in combination with metformin in children and adolescents with T2D with inadequate glycemic control. The initial plan was to enroll a total of 358 patients; however, due to a very slow recruitment rate indicating that completion of the trial within a relevant timeframe would not be possible, it was decided to stop further enrollment after 17 months. This resulted in the recruitment of 42 patients. No efficacy

| Time from randomization | HbA1c, %   | Insulin detemir | NPH insulin |
|------------------------|------------|-----------------|-------------|
| Week –2                | 8.6 (7.3; 10.3) | 9.0 (7.1; 10.5)   |
| Week 8                 | 7.7 (6.2; 10.2) | 8.1 (6.2; 11.9)   |
| Week 16                | 7.5 (5.7; 9.6)  | 7.8 (6.2; 9.7)    |
| Week 26                | 7.9 (5.3; 10.9) | 8.1 (5.9; 11.0)   |

Data are median (min; max)

FAS full analysis set, NPH neutral protamine Hagedorn

Table 3 Secondary efficacy endpoints after 26 weeks of treatment

| Endpoint                        | Insulin detemir (n = 20) | NPH insulin (n = 22) |
|---------------------------------|--------------------------|----------------------|
| FPG, mmol/L                     | 7.66 (2.63)              | 7.86 (2.88)          |
| Change from baseline            | -0.335 (2.961)           | -2.332 (4.147)       |
| Body weight, SDS                | 1.538 (0.690)            | 1.358 (0.840)        |
| Change from baseline            | 0.006 (0.192)            | 0.098 (0.139)        |
| Body weight, kg                 | 77.79 (16.16)            | 77.20 (24.60)        |
| Change from baseline            | 1.89 (3.40)              | 4.00 (3.75)          |
| Height, SDS                     | -0.129 (1.057)           | -0.185 (1.046)       |
| Change from baseline            | -0.042 (0.167)           | -0.019 (0.152)       |
| BMI, kg/m²                      | 29.09 (4.40)             | 28.90 (7.20)         |
| Change from baseline            | 0.35 (1.22)              | 1.20 (1.29)          |
| BMI, SDS                        | 1.694 (0.405)            | 1.538 (0.658)        |
| Change from baseline            | 0.013 (0.176)            | 0.086 (0.132)        |
| Mean 7-point SMBG, mmol/L       | 8.28 (2.72)              | 8.45 (3.06)          |

Data are mean (SD) unless specified

BMI body mass index, FPG fasting plasma glucose, NPH neutral protamine Hagedorn, SDS standard deviation score, SMBG self-measured blood glucose

a Mean 7-point SMBG profile is calculated as the arithmetic mean of all 7 points

b Within the last 14 weeks of treatment and only subjects who had been exposed for minimum 14 weeks included
conclusions can be drawn given the low number of recruited patients, but the study did not present any new safety issues.

From baseline to 26 weeks after start of treatment, the mean change in both HbA1c and FPG decreased for both the insulin detemir and NPH insulin groups. The observed trend in HbA1c reduction seemed to decline after 16 weeks in both treatment groups. Although no efficacy conclusions can be drawn due chiefly to the low number of patients recruited, the upward trend in HbA1c after 16 weeks may be attributable to treatment-independent factors, such as rapid beta-cell deterioration or trial fatigue. The difference in the change from baseline in FPG may have been driven by the different mean FPG values observed between the treatment groups at baseline (i.e., the higher baseline FPG value observed in the NPH insulin group). Additionally, considering the limitations of the study, the rate of severe or BG-confirmed hypoglycemic episodes was numerically lower in the insulin detemir versus the NPH insulin group. These efficacy and safety findings are aligned with what has been observed in studies in adults with T2D [5].

Due to the often rapid deterioration of glycemic control witnessed in T2D in youth compared with adults [16], providing early, efficacious, and safe treatment options is critical. This need is exacerbated when clinicians are reluctant to start insulin treatment in people with T2D (i.e., “clinical inertia”) [11]. Although the low number of patients included in this trial prevents the drawing of firm conclusions, the results may provide clinically relevant insights into the management of T2D in children and adolescents.

It is important to discuss the wider context of this clinical trial. Specifically, recruitment is problematic in clinical trials involving children and adolescents with T2D, mainly due to poor engagement [16, 17, 21]. For instance, previous analyses have indicated that clinical trial recruitment is generally low in this population and can range from 3.3 to 65% [17]. While the recruitment rate of the current trial was low (12% in 17 months), retention (93%) was excellent, ranking at the higher end of the range of results reported from other studies (74–100%) [6, 17]. This high retention may be explained by the relatively short duration of the study and the inclusion of a lifestyle program that involved the patient’s family and was based on a behavioral weight-loss approach. The TODAY study, which used a very similar interventional lifestyle program, showed a reduction in treatment adherence over 5 years across all treatment groups, as well as a reduction in attendance rate at scheduled lifestyle program visits from 75.2% in the first 2 years to 53.6% thereafter [25]. However, patients who had a lifestyle program as an add-on to metformin were at least 10% more adherent to their medication compared with those patients who were treated with metformin alone, or with metformin plus rosiglitazone, suggesting that a family-based behavioral program may help improve trial retention [25]. The higher retention observed in our study may have also been partly driven by the care and monitoring required when intensifying with basal insulin, which was not available as a treatment option in the TODAY trial.

To improve outcomes for this population, increasing the recruitment period of clinical trials may help researchers attract the required number of patients; however, there are wider issues that should also be addressed. Indeed, poor engagement in clinical trials is possibly indicative of the failure of this population to engage with routine clinical care [19], and it can be argued that this population requires a holistic/multidisciplinary approach to promote engagement and improve outcomes. To conclude, no new safety issues with insulin detemir or NPH insulin in children and adolescents with T2D were observed.

Acknowledgments The iDEAt2 trial was sponsored by Novo Nordisk A/S. In addition, medical writing and submission support were provided by Dr. Ugo Battaglia and Erin Slobodian of Watermeadow Medical—an Ashfield company, part of UDG Healthcare PLC, funded by Novo Nordisk A/S.

Author contributions MDW, MB, FL, BL, AL, OT, and NZL are responsible for reported research; have participated in the interpretation of data, drafting, or revising the manuscript; and have approved the manuscript as submitted.

Table 4 Treatment-emergent hypoglycemic events

|                          | Insulin detemir (n = 20) | NPH insulin (n = 22) |
|--------------------------|--------------------------|---------------------|
|                          | N (%) E R                | N (%) E R           |
| Severe                   | 0                        | 0                   |
| Symptomatic BG-confirmed | 1 (5.0) 4 0.4            | 5 (22.7) 12 1.1     |
| Nocturnal severe         | 0                        | 0                   |
| Nocturnal symptomatic BG-confirmed | 0 | 1 (4.5) 1 0.1 |

Hypoglycemia was classified as “severe” (American Diabetes Association classification) if the episode required assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions, and as “symptomatic BG-confirmed” (Novo Nordisk classification) if the episode was not severe and with a plasma glucose value < 3.1 mmol/L (< 56 mg/dL) with symptoms. Nocturnal episodes are the episodes reported with the time of onset between 2300 and 0659 hours, both inclusive.

% percentage of patients, BG blood glucose, E number of episodes, N number of patients, NPH neutral protamine Hagedorn, R event rate per patient-year of exposure.
Funding The iDEA2 trial was sponsored by Novo Nordisk A/S. Medical writing and submission support were provided by Dr. Ugo Battaglia and Erin Slobodian of Watermeadow Medical—an Ashfield company, part of UDG Healthcare PLC, funded by Novo Nordisk A/S.

Compliance with ethical statements

Conflict of interest BL and OT are employees of Novo Nordisk. The remaining authors have no conflicts of interest to declare.

Informed consent Written informed consent was collected from all patients or legally acceptable representatives.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. American Diabetes Association (2017) Standards of medical care in diabetes-2018: summary of revisions. Diabetes Care 41:S1–S159
2. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badarou A, Talton JW, Crume T, Liese AD, Merchant AT, Lawrence JM, Reynolds K, Dolan L, Liu LL, Hamman RF, SEARCH for Diabetes in Youth Study (2014) Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311:1778–1786
3. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M, Donaghue KC (2006) Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 29:1300–1306
4. Fazeli Farsani S, van der Aa MP, van der Vorst MMJ, Knibbe CAJ, de Boer A (2013) Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches. Diabetologia 56:1471–1488
5. Frier BM, Russell-Jones D, Heise T (2013) A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes Obes Metab 15:978–986
6. Gemmill JAL, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI (2011) Clinical trials in youth with type 2 diabetes. Pediatri Diabetes 12:50–57
7. Hannon TS, Arslanian SA (2015) The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci 1353(1):113–137
8. Hermansen K, Davies M, Dereczinski T, Martinez RG, Clauson P, Home P (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29:1269–1274
9. Imperatore G, Boyle JP, Thompson TJ, SEARCH for Diabetes in Youth Study Group et al (2012) Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 35:2515–2520
10. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3–19
11. Khunti K, Millar-Jones D (2017) Clinical inertia to insulin initiation and intensification in the UK: a focused literature review. Prim Care Diabetes 11:3–12
12. Kuczynski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 2002:1–190
13. Lawrence JM, Imperatore G, Dabelea D, SEARCH for Diabetes in Youth Study Group et al (2014) Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002–2009. Diabetes 63:3938–3945
14. Ludvigsson J (2004) Prevention of adverse events in juvenile diabetes. Minerva Pediatr 56:277–290
15. Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Ison S, Dolan L, Imperatore G, Linder B, Marcovina S, Pettit DJ, Pihoker C, Saydah S, Wagenknecht L, SEARCH for Diabetes in Youth Study (2017) Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. N Engl J Med 376:1419–1429
16. Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, Hannon TS, Huang TTK, Lynch JL, Powell J, Sellers E, Tamborlane WV, Zeitler P (2016) Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care 39:1635–1642
17. Nguyen TT, Jayadeva V, Cizza G, Brown RJ, Nandagopal R, Rodriguez LM, Rother KI (2014) Challenging recruitment of youth with type 2 diabetes into clinical trials. J Adolesc Health 54:247–254
18. Pinhas-Hamiel O, Zeitler P (2007) Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 369:1823–1831
19. Reinehr T, Schober E, Roth CL, Wiegand S, Holl R, DPV-Wiss Study Group (2008) Type 2 diabetes in children and adolescents in a 2-year follow-up: insufficient adherence to diabetes centers. Horm Res 69:107–113
20. Strandberg AY, Khanfir H, Mäkkimattila S, Saukkonen T, Strandberg TE, Hovi F (2017) Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults. Ann Med 49:357–364
21. Tamborlane WV, Klingensmith G (2013) Crisis in care: limited treatment options for type 2 diabetes in adolescents and youth. Diabetes Care 36:1777–1778
22. Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco AM, Kinduryte O, Danne T (2015) Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatri Diabetes 16:164–176
23. TODAY Study Group (2010) Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes 34:217–226
24. TODAY Study Group (2013) Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care 36:1749–1757
25. TODAY Study Group, Zeitler P, Hürt K et al (2012) A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366:2247–2256
26. Young TK, Dean HJ, Flett B, Wood-Steiman P (2000) Childhood obesity in a population at high risk for type 2 diabetes. J Pediatri 136:365–369
27. Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, Maahs D, International Society for Pediatric and Adolescent Diabetes (2014) Type 2 diabetes in the child and adolescent. Pediatri Diabetes 15(Suppl. 20):26–46